Modern healthcare is changing rapidly. Patients no longer want to spend countless hours traveling to hospitals or infusion centers for treatments that can safely be administered elsewhere. At the same time, healthcare providers and pharmaceutical companies are looking for ways to improve patient comfort while maintaining high standards of care. These changes have created growing interest in smart drug delivery systems that allow patients to receive advanced therapies outside traditional clinical settings.
Among the companies helping drive this transformation is KORU Medical Systems. The company specializes in large-volume subcutaneous infusion technology and has spent decades developing solutions that support the delivery of complex therapies in home and ambulatory care environments. Through its Freedom™ Infusion System, KORU Medical is helping patients receive prescribed treatments with greater convenience while supporting healthcare providers and pharmaceutical partners seeking effective drug delivery solutions.
As biologic medicines and specialty therapies continue to grow worldwide, KORU Medical’s technology is becoming increasingly important in the evolution of patient-centered healthcare.
KORU Medical Systems Builds Solutions Around Patient Needs
KORU Medical Systems develops, manufactures, and commercializes specialty infusion solutions designed for large-volume subcutaneous drug delivery. The company’s primary focus is on helping patients who require recurring treatment regimens for chronic diseases and other long-term health conditions. The company’s approach centers on providing patients with greater flexibility in how and where they receive treatment. Rather than requiring repeated visits to hospitals or infusion centers, KORU’s technology supports administration in home settings when prescribed and appropriate.
This patient-focused philosophy has shaped the company’s development efforts for many years. KORU aims to simplify treatment delivery while supporting the safety, consistency, and effectiveness required for specialized therapies. The growing demand for home-based care has increased interest in technologies that make treatment more accessible. KORU Medical’s infusion solutions have positioned the company within an expanding segment of the healthcare industry focused on patient convenience and improved quality of life.
The Freedom™ Infusion System Powers KORU’s Smart Drug Delivery Strategy
At the center of KORU Medical’s portfolio is the Freedom™ Infusion System. The system includes the FREEDOM60® Syringe Infusion Driver, FreedomEdge® Syringe Infusion Driver, Precision Flow Rate Tubing™, and High-Flo Subcutaneous Safety Needle Sets™. The Freedom System first received FDA clearance in 1994 and has since been used to support subcutaneous infusion therapies in home and ambulatory care settings. The platform was designed to provide a simple and reliable approach to administering medications that require larger infusion volumes than traditional injections.
One of the system’s key advantages is its compatibility with prefilled syringes. These syringes can be prepared with exact medication doses before use, reducing preparation steps and helping streamline treatment administration. As pharmaceutical companies develop more biologic therapies, the need for practical delivery systems continues to grow. The Freedom System was developed to address these challenges by supporting therapies that require recurring administration over extended periods. The company’s focus on ease of use and patient convenience reflects broader healthcare trends that prioritize treatment options closer to home whenever medically appropriate.
Supporting the Growing Large-Volume Subcutaneous Infusion Market
The market for subcutaneous drug delivery has expanded significantly in recent years. Pharmaceutical companies increasingly seek alternatives to traditional intravenous administration because subcutaneous delivery can offer greater convenience for both patients and healthcare providers. KORU Medical has focused its efforts on serving this evolving market. The company’s technology is designed to support therapies requiring larger infusion volumes and specialized delivery methods.
As more biologics enter the market, healthcare systems are exploring ways to reduce treatment burdens while maintaining therapeutic effectiveness. Large-volume subcutaneous infusion has emerged as one of the most promising approaches for achieving that goal. KORU’s continued investment in this area demonstrates the company’s commitment to addressing changing healthcare needs and supporting future treatment innovations.
Partnership with SCHOTT Pharma Expands Drug Delivery Opportunities
In June 2024, KORU Medical Systems and SCHOTT Pharma announced a collaboration focused on advancing large-volume subcutaneous infusion solutions. SCHOTT Pharma manufactures TOPPAC® prefillable polymer syringes that are designed to work with KORU Medical’s Freedom™ Infusion System. The collaboration aims to support the growing demand for therapies that require recurring dosing schedules, including treatments used in chronic disease management.
The partnership brings together expertise in drug containment and drug delivery. By combining compatible syringe technology with infusion delivery systems, the companies seek to support pharmaceutical manufacturers developing new therapies for subcutaneous administration. Collaborations of this nature are becoming increasingly important as healthcare companies work together to create integrated treatment solutions that improve the patient experience.
FDA Clearance Expands the Use of FreedomEdge®
Regulatory milestones remain an important part of KORU Medical’s growth story.
In January 2026, the company announced that it had received FDA 510(k) clearance for the delivery of RYSTIGGO® (rozanolixizumab-noli) using the FreedomEdge® Infusion System. RYSTIGGO® is commercialized globally by UCB and is used in the treatment of generalized myasthenia gravis (gMG). The clearance expanded the FreedomEdge® label and increased flexibility for healthcare professionals administering the therapy. It also represented another example of how KORU Medical continues to work with pharmaceutical companies and healthcare providers to support specialized treatment delivery.
Regulatory approvals and clearances are significant because they demonstrate that a device has met established requirements for safety and effectiveness for its intended use. For KORU Medical, each additional clearance strengthens the potential applications of its infusion technology and broadens opportunities for future collaborations.
Clinical Trial Participation Demonstrates Confidence in the Technology
KORU Medical’s infusion systems are also being used to support clinical development programs. In 2024, the company announced a supply agreement for a Phase III clinical trial involving a novel endocrinological biologic therapy. The Freedom System was selected following validation testing and will be used to administer the investigational treatment during the study.
Clinical trials represent an important stage in the development of new therapies. Drug developers carefully evaluate delivery methods during these programs because administration systems can influence both patient experience and treatment outcomes.
Selection for a late-stage clinical trial highlights confidence in the Freedom System’s capabilities and its suitability for supporting advanced biologic therapies. As more pharmaceutical companies pursue innovative treatments, participation in clinical development programs may create additional opportunities for KORU Medical’s technology.
Contributing to the Future of Subcutaneous Drug Development
KORU Medical joined the Subcutaneous Drug Development & Delivery Consortium in 2022, becoming one of the first device-focused companies included in the organization. The consortium brings together stakeholders involved in advancing subcutaneous therapies and delivery technologies. Its members collaborate on topics related to innovation, best practices, and the future direction of drug delivery.
Participation allows KORU Medical to contribute its expertise while remaining engaged with developments across the pharmaceutical and medical technology industries. As healthcare increasingly shifts toward patient-friendly treatment options, collaboration between device manufacturers and pharmaceutical companies will likely play an important role in shaping future solutions.
Adam Kalbermatten Brings Extensive Drug Delivery Experience
KORU Medical announced a leadership transition in 2026 when Adam Kalbermatten was appointed President effective March 15, 2026, and Chief Executive Officer effective July 1, 2026. He succeeds Linda Tharby, who led the company through a period of growth and innovation.
Kalbermatten brings extensive experience in medical technology, pharmaceutical services, and advanced drug delivery systems. Before joining KORU Medical, he served as Vice President and General Manager of Advanced Drug Delivery Systems at Becton Dickinson (BD), where he led initiatives across the company’s injectable drug delivery portfolio. His responsibilities included supporting growth strategies and helping expand drug delivery solutions for pharmaceutical customers.
Earlier in his career, he served as Chief Executive Officer of ZebraSci, a company specializing in analytical and drug-device combination product development services. During his leadership, the company executed a successful turnaround strategy that ultimately resulted in its acquisition by BD. Kalbermatten also held senior global leadership positions at Terumo Medical Corporation, including Worldwide Director of Marketing and Worldwide Director of Business Development. These roles provided significant experience in international healthcare markets and drug delivery technologies.
His educational background combines engineering expertise with healthcare business knowledge. He earned a Bachelor of Engineering in Mechanical Engineering and a Master of Engineering in Engineering Management from Stevens Institute of Technology. He later completed an MBA with concentrations in Finance and Healthcare from Columbia Business School. His experience aligns closely with KORU Medical’s focus on infusion technologies and pharmaceutical partnerships. As CEO, he will lead the company’s next phase of growth and innovation in the smart drug delivery sector.
Financial Growth Reflects Expanding Market Demand
KORU Medical has reported steady business growth as demand for subcutaneous infusion solutions continues to increase. The company reported revenue growth during recent fiscal periods, reflecting broader adoption of its infusion technologies and increasing activity within the biologics and specialty pharmaceuticals market.
Continued investment in research and development remains an important part of KORU Medical’s strategy. The company has consistently allocated resources toward product improvements and future innovation initiatives designed to support evolving healthcare needs. These investments demonstrate a long-term commitment to advancing infusion technology and supporting the future of home-based treatment.
KORU Medical Continues to Shape the Future of Smart Drug Delivery
The healthcare industry is moving toward solutions that improve patient access, convenience, and quality of life. KORU Medical Systems has positioned itself within this transformation through its focus on large-volume subcutaneous infusion technology and patient-centered treatment delivery. The Freedom™ Infusion System, strategic partnerships, regulatory achievements, and participation in clinical development programs have helped establish the company as an important contributor to the evolving drug delivery landscape.
With Adam Kalbermatten preparing to guide the company’s future direction, KORU Medical continues to build on decades of experience in infusion technology. As demand for home-based treatment options grows, the company’s commitment to innovation and patient-focused care places it in a strong position to support the next generation of healthcare delivery.
Smart drug delivery is no longer simply about transporting medicine from one place to another. It is about improving the patient experience, supporting healthcare efficiency, and helping advanced therapies reach the people who need them most. Through its ongoing work in large-volume subcutaneous infusion, KORU Medical Systems continues to play a meaningful role in that transformation.
